Quest Diagnostics Inc (DGX)
Fair bewertetFundamental
73
Kurs
$233.07
Marktkapitalisierung
$26.23B
Teil 1 · Was das Unternehmen wert ist
Übersicht
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; healthcare IT healthcare providers and payers; testing and medical director services at hospital laboratories; test offerings in cardiometabolic and endocrine; cancer; clinical drug monitoring and toxicology; infectious disease, including autoimmune; neurology diagnostics, including Alzheimer's disease; and women's health, such as prenatal genetic; workplace drug testing, testing urine, hair, and oral fluid specimens services; and employer population health services, including biometric screenings, flu shots, and related preventative services. Further, it provides population health solutions; extended care services; develops in vitro diagnostic tests; laboratory diagnostic information and digital health connectivity systems; underwriting support services, including data gathering, paramedical examinations, and clinical laboratory testing and analytics; and national specimen collection and health data solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
Generated on 18. September 2026 with claude-haiku-4-5 — shared with all users
Labcorp is the other national US clinical laboratory network, selling the same routine and specialty test menu to the same physicians, hospitals, health plans and employers, and competing directly for the same managed-care contracts and hospital outreach deals.
Through Sonic Healthcare USA it runs a large network of regional clinical laboratories serving American physicians and hospitals, the same customers Quest bids for, and it is also Quest's main rival in Canada after the LifeLabs acquisition.
As one of the largest US reference laboratories, it takes in specialty and esoteric testing sent out by hospitals and physician practices across the country, the higher-value volume Quest's advanced diagnostics business targets.
A non-profit national reference laboratory owned by the University of Utah that competes for the same hospital and health-system send-out testing contracts Quest pursues with its hospital lab services.
It sells oncology and molecular testing to US pathologists, oncologists and hospitals, overlapping with the cancer and genetic testing line Quest is expanding within its advanced diagnostics.
Its clinical diagnostics division runs routine and specialty testing laboratories, including in the United States, competing for the same physician and hospital testing volumes as Quest.
Bilanz & Liquidität
Umsatz
$11.56B
Letzte 12 Monate (bis 30.6.2026)
Nettogewinn
$1.06B
Letzte 12 Monate (bis 30.6.2026)
Freier Cashflow
$1.36B
Gesamtes Eigenkapital
$7.17B
Gesamtverbindlichkeiten
$9.02B
Current Ratio
1.59
Zinsdeckungsgrad
6.37
Schulden/EBITDA
3.00
Gewinn je Aktie
Umsatz & Nettogewinn
Freier Cashflow
Ertragsaufschlüsselung
Historische Aufstellung
Margen im Zeitverlauf
Verschuldung im Zeitverlauf
Wie schwer die Schulden wiegen
Wachstumsraster
Wachstum — Umsatz
Innerer-Wert-Schätzung
Innerer Wert
$222.23
Aktueller Kurs
$233.07
Sicherheitsmarge
-4.9%
Innerer-Wert-Spanne
$155.33 - $289.13
Streubreite zwischen den verwendeten Bewertungsmethoden, kein statistisch kalibriertes Konfidenzintervall.
Bewertungsmethoden
Bewertungskennzahlen
P/E-Verhältnis
24.74
ROE
13.8%
P/B-Verhältnis
3.42
P/FCF
19.07
Bruttomarge
33.1%
ROIC
8.5%
Rentabilitäts-Radar
Wertschöpfung (Wettbewerbsvorteil)
ROIC
8.5%
WACC
7.1%
ROIC − WACC
+1.4 pp
Der ROIC übersteigt die Kapitalkosten: Das Unternehmen schafft Wert für die Aktionäre.
Fundamentalanalyse-Kriterien
Bestanden (20)
- EPS shows upward trend
- EPS CAGR 9.39%
- Price CAGR 9.85%
- ROIC 8.5%
- Gross Margin 33.1%
- P/FCF 19.07
- Debt/Equity ratio
- Operating Margin 14.1%
- Positive Free Cash Flow
- Current Ratio
- Interest Coverage
- Debt/EBITDA
- Return on Tangible Assets
- ROE 14.5%
- Analyst Consensus 57% Buy
- Earnings Surprise avg 4.8%
- Earnings Quality (OCF/NI) 1.79
- Share Dilution 0.1%
- Net Margin Trend 9.2% vs 9.0%
- Piotroski F-Score 8/9
Nicht bestanden (6)
- P/B Ratio 3.42
- CapEx intensity
- Low reliance on intangibles
- Price below Graham Number
- DCF valuation (Overvalued)
- Revenue Growth 5Y 3.2%
Nicht verfügbar (2)
- Dividend Payout NaN%
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
Starke finanzielle Gesundheit
Gewinnqualität
Hohe Qualität: Gewinne durch Cashflow gedeckt
Aktienverwässerung
Aktienanzahl ist stabil
Institutionelle Beteiligungen
Unternehmensführung
Führungsteam
| Name | Position | Alter |
|---|---|---|
| Mr. James E. Davis | Chairman, CEO & President | 62 |
| Mr. Sam A. Samad | Executive VP & CFO | 55 |
| Mr. Michael E. Prevoznik J.D. | Senior VP & General Counsel | 63 |
| Ms. Catherine T. Doherty | Executive Vice President of Regional Businesses | 62 |
| Mr. Karthik Kuppusamy Ph.D. | Senior Vice President of Clinical Solutions | 55 |
| Mr. Michael J. Deppe | Senior VP, Corporate Controller & Chief Accounting Officer | 58 |
| Mr. Murali Balakumar | Senior VP and Chief Information & Digital Officer | - |
| Ms. Damini Chokshi | Vice President of Investor Relations | - |
| Ms. Kristin Lee Wallace Esq. | Senior VP & Chief Compliance Officer | - |
| Mr. Garry Clark | Senior VP and Chief Marketing & Communications Officer | - |
Prüfungsrisiko
6
Vorstandsrisiko
7
Vergütungsrisiko
2
Aktionärsrechterisiko
2
Teil 2 · Der Preis und der Einstiegszeitpunkt
Dieser Teil sagt nicht, ob das Unternehmen etwas taugt: Er hilft bei der Wahl des Kaufzeitpunkts, nachdem die Fundamentaldaten überzeugt haben. Enthalten: technische Analyse, Potenzial, historische Drawdowns, Gamma-Exposure.
Dokumente
- Dokument ansehen
Jahresbericht (10-K)
Ein jährlicher Überblick über das Geschäft, die Finanzergebnisse und die Risiken des Unternehmens.
Eingereicht am 2026-02-26
- Dokument ansehen
Quartalsbericht (10-Q)
Ein Update zur finanziellen Entwicklung der letzten drei Monate.
Eingereicht am 2026-07-23
- Dokument ansehen
Ad-hoc-Meldung (8-K)
Eine Mitteilung über ein wichtiges Ereignis, etwa einen Führungswechsel oder eine bedeutende Ankündigung.
Eingereicht am 2026-07-23
via SEC EDGAR
Ertragshistorie
via SEC EDGAR
Latest News
Recent headlines for DGX, sourced from Markets Gazette.